CClinicalTrials.gg
Status unknownNCT03639103DMMOUpdated Aug 20, 2018

Clinical and Radiographic Outcomes of Distal Metatarsal Metaphyseal Osteotomy for Central Primary Metatarsalgia

An observational study in Metatarsalgia Bilateral, sponsored by University of Padova. Status unknown at 1 site in Italy. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-20.

Sponsored by University of Padova · Observational

The sponsor has not verified this record recently (last verified Aug 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The primary propose of this prospective study is to specifically evaluate the safety and effectiveness of Minimally Invasive Distal Metatarsal Metaphyseal Osteotomy (DMMO) in treating patients with persistent central primary metatarsalgia, associated or not to hallux valgus and lesser toe deformities, identifying possible contraindications in relation to some demographic parameters (age, gender, BMI, and smoking). The second objective is to verify the potential of DMMO in restoring a harmonious foot morphotype according to Maestro's criteria and if these radiographic parameters are correlated with clinical outcomes, maintaining the predictive value of these criteria during preoperative planning also for this percutaneous surgery.

Read the detailed description

A consecutive series of patients with metatarsalgia is consecutively enrolled and treated by DMMO. According to Maestro criteria, pre-operative planning is carried out by both clinical and radiological assessment. Patient demographic data, AOFAS scores, 17-Foot Functional Index, Manchester-Oxford Foot Questionnaire, SF-36, VAS, and complications are recorded. Maestro parameters, relative morphotypes, and bone callus formation are assessed. Statistical analysis is carried out (p \< 0.05).

02

Conditions studied

  • Metatarsalgia Bilateral
03

In context

Lead sponsor

University of Padova is the lead sponsor of 210 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with diagnosis of central primary metatarsalgia between M2 and M4 of a biomechanical etiology in the plantar foot area are enrolled consecutively and prospectively with precise inclusion criteria. Ages range from 18 to 90 years.

Inclusion criteria

  • forefoot persistent pain;
  • presence or not of forefoot plantar hyperkeratosis lesions;
  • ineffective conservative and orthotic treatment performed for at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • arthritis and stiffness of MTP joint;
  • congenital deformities of the foot;
  • hallux rigidus;
  • Freiberg infraction;
  • Morton's neuroma;
  • diagnosis of rheumatic, metabolic, neurologic, infective, or psychiatric pathologies;
  • previous trauma;
  • foot and ankle surgery,
  • any form of secondary or iatrogenic metatarsalgia.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
12 Years
Patient registry
Yes

Interventions

  • ProcedureDistal Metatarsal Metaphyseal Osteotomy (DMMO)

    The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.

    Also known as: DMMO PERCUTANEOUS SURGERY

06

What researchers measure

Primary outcomes

  1. Evaluation of the 100-point hallux metatarsophalangeal-interphalangeal scale (AOFAS) changes

    The AOFAS score includes 9 questions related to pain, function and alignment; a score of 90-100 is considered excellent; 75-89 as good; 50-74 as fair and less than 49 points is considered a failure or a poor outcome.

    Time frame: preoperatively, 3-, 6-, 12-months

  2. Evaluation of the Foot Functional Index changes

    The Foot Functional Index to measure the persistence of pain, disability, and restriction of activity with 17 number rating scales from 0 to 10. The maximum score is 100, which indicates complete disability.

    Time frame: preoperatively, 3-, 6-, 12-months

  3. Evalutation of the Manchester-Oxford Foot Questionnaire changes

    The Manchester-Oxford Foot Questionnaire to establish how frequent the restrictions in specific situations were, including 16 questions divided into three basic domains: pain (five), walking/standing (seven), and social interaction (four). Scores for each domain are calculated by summing the responses to each item within a given domain. Raw scores can be converted to a 0-100 metric where 100=most severe.

    Time frame: preoperatively, 3-, 6-, 12-months

Secondary outcomes

  1. Radiographic classification according to Maestro and Besse criteria

    Our sample is classified radiographically according to Maestro and Besse criteria, adding to this classification one more group to include those feet that did not reflect any morphotype as defined by Maestro parameters. The radiographic evaluations includes the Maestro criteria index using the preoperative and the last follow up. The relative length of each metatarsal is determined by drawing a line perpendicular to the axis of the foot and then measuring the distances (in millimeters) from each metatarsal head to this line , while also taking into account the relationship between the length of metatarsal M1 and the length of the remaining metatarsal bones.

    Time frame: before surgery, at one-month after surgery and at different follow-ups (3-, 6-, 12-month, and last)

07

Study locations

1 of 1 sites recruiting
  • Padua Univeristy Orthopaedic Clinic
    Padova, 35128, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03639103
Lead sponsor
University of Padova
Responsible party
Carlo Biz (Orthopedic surgeon, Assistant Professor, University of Padova) — Principal investigator
First posted
Aug 20, 2018
Start date
Jan 1, 2009
Primary completion
Dec 31, 2013
Completion
Dec 31, 2021 (estimated)
Last update
Aug 20, 2018

Study contacts

CARLO BIZ, MD
Contact
carlo.biz@unipd.it
00393483608819
LODOVICA GAMBATO, DR
Contact
lodovica.gambato@aopd.veneto.it
00390498212342
Carlo Biz, MD
principal investigator · Padua University Orthopaedic Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion